Replies to post #244150 on Biotech Values

[DewDiligence]

IMRA—>ELVN effective tomorrow, pursuant to previously announced reverse-merger:

https://www.globenewswire.com/news-release/2023/02/22/2613712/0/en/ARS-Pharmaceuticals-Reacquires-European-Marketing-Rights-to-neffy-ARS-1-for-the-Treatment-of-Type-I-Allergic-Reactions-Including-Anaphylaxis.html

A 1:4 reverse split will be executed in conjunction with the merger closing.